Gut
-
Randomized Controlled Trial Multicenter Study
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
The authors tested whether the anti-interleukin (IL)-17A monoclonal antibody secukinumab was safe and effective for the treatment of active Crohn's disease. ⋯ This trial was registered at ClinicalTrial.gov with the number NCT01009281.